NCT01352962 2026-01-05
Gemcitabine, Carboplatin, and Lenalidomide for Treatment of Advanced/Metastatic Urothelial Cancer and Other Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
Clinical Trials
19 trialsNCT01326871 2024-06-25
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
Altor BioScience
Phase 1/2 Completed
NCT00942331 2023-10-16
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00005644 2023-06-22
Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00004223 2023-06-18
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02437370 2022-10-18
Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer
University of California, Davis
Phase 1 Completed
NCT00478361 2020-10-09
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02178241 2019-12-16
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT02665039 2019-10-08
VINGEM
Karolinska University Hospital
Phase 2 Completed
NCT02300610 2019-08-01
Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01191892 2019-05-16
Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer
Cardiff University
Phase 2 Completed
NCT01089088 2018-10-26
Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)
Cardiff University
Phase 2 Completed
NCT01090466 2018-02-06
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
Cardiff University
Phase 1/2 Completed
NCT00014274 2013-06-12
Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2/3 Completed
NCT00022191 2013-06-12
Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00045630 2013-05-27
S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium
SWOG Cancer Research Network
Phase 2 Completed
NCT00055835 2013-01-31
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
SWOG Cancer Research Network
Phase 2 Completed
NCT00080795 2012-10-22
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00006351 2012-09-24
SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed